Nasdaq-listed SciClone Pharmaceuticals Inc. has been privatised and delisted from the New York-based stock exchange by a consortium consisting of entities affiliated with GL Capital Management GP Limited (GL Capital), Bank of China Group Investment Limited (BOCGI), CDH Investments, Ascendent Capital Partners and Boying.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com